Idylla EGFR Lung Trial

Status unconfirmed

Conditions studied: Lung Cancer, Technology, Oncology

In brief

This retrospective, observational study will compare the results of a BioCartis' EGFR mutation test on the Idylla platform with test results from SoC pathology results from tissue biopsies in the same setting. A comparable rapid testing platform for EGFR may serve as a more accessible means to diagnose, and overall, more patients treated successfully with targeted therapies. Up to 150 samples will be tested and compared with existing results.

Key facts

Study ID

NCT04962191

Run by

Anthony Magliocco

People needed

150

Starts

2021-08-01

Expected to finish

2023-01-01

Last updated by the study team

2021-07-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed with primary lung cancer
• Data from primary diagnosis must be included in pathology report or data entry.
• Detailed pathology report included for all samples

You may not qualify if…

• Limited or no tissue available
• Only tissue available is from fine needle aspiration
• Tissue blocks older than 5 years old

Where it is running

• 6555 Sanger Rd, Suite 260 — Orlando, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.